Weekly Sepsis Research Analysis
This week’s sepsis literature highlights converging advances across mechanistic immunometabolism, rapid diagnostics, and pragmatic clinical evidence. A high-impact mechanistic study links pathologic itaconate–AIM2 alkylation to macrophage PANoptosis, opening a new druggable node for hyperinflammatory sepsis. Diagnostic innovation (MALCA) enables same-day carbapenemase detection and typing from routine antibiograms, promising faster targeted therapy for drug-resistant sepsis. A translational mult
Summary
This week’s sepsis literature highlights converging advances across mechanistic immunometabolism, rapid diagnostics, and pragmatic clinical evidence. A high-impact mechanistic study links pathologic itaconate–AIM2 alkylation to macrophage PANoptosis, opening a new druggable node for hyperinflammatory sepsis. Diagnostic innovation (MALCA) enables same-day carbapenemase detection and typing from routine antibiograms, promising faster targeted therapy for drug-resistant sepsis. A translational multi-system paper identifies OGDH as an immunometabolic driver of macrophage M1 polarization and ferroptosis in sepsis-associated lung injury with an available inhibitor showing preclinical benefit.
Selected Articles
1. The alkylation of AIM2 by itaconate mediates macrophage PANoptosis during sepsis.
High pathophysiologic concentrations of itaconate covalently alkylate AIM2 at C113, stabilizing and activating AIM2 to drive ASC oligomerization, PANoptosome assembly, and macrophage PANoptosis; AIM2 C113A mutation abrogates these effects and in vivo data show the axis exacerbates systemic sepsis.
Impact: Provides a first-in-class mechanistic link between an immunometabolite and AIM2-driven PANoptosis in sepsis, identifying a novel, druggable node that reframes itaconate’s role and opens new therapeutic approaches.
Clinical Implications: Although preclinical, this axis suggests targeting AIM2 modification or downstream PANoptosis as strategies to preserve macrophage populations and limit hyperinflammation in severe sepsis; human validation of itaconate/AIM2 status will be needed prior to trials.
Key Findings
- Itaconate covalently alkylates AIM2 at cysteine 113, stabilizing and activating AIM2.
- Activated AIM2 drives ASC oligomerization, PANoptosome assembly, and macrophage PANoptosis; AIM2 C113A mutation abolishes effects.
- In vivo models confirm itaconate–AIM2 axis exacerbates systemic sepsis.
2. Direct carbapenemase typing from disc diffusion antibiograms with MALCA (MAchine Learning CArbapenemase).
MALCA, a stepwise random-forest ML pipeline trained on routine disc diffusion antibiograms (11,992 isolates, externally validated on 8,514), achieved >96% sensitivity and specificity for carbapenemase detection and >97% sensitivity/>98% specificity for common types (OXA-48-like, NDM, KPC), enabling rapid, reagent-free typing to guide earlier targeted therapy.
Impact: Diagnostic innovation that leverages existing lab outputs to deliver same-day mechanism-level resistance information—potentially shortening time-to-appropriate therapy and improving outcomes in drug-resistant sepsis outbreaks.
Clinical Implications: Integrating MALCA into laboratory workflows could enable same-day carbapenemase typing to inform early antibiotic selection (e.g., ceftazidime–avibactam vs aztreonam–avibactam) and stewardship decisions, pending prospective implementation studies measuring clinical outcomes.
Key Findings
- MALCA-22 and MALCA-8 classifiers trained on 11,992 isolates and externally validated on 8,514 isolates.
- Both classifiers achieved >96% sensitivity/specificity for CPE detection; >97% sensitivity and >98% specificity for common carbapenemases (OXA-48-like, NDM, KPC).
- Outperformed established European/French CPE screening algorithms using only routine antibiogram data.
3. OGDH primes macrophage for M1-like polarization and ferroptosis in sepsis associated acute lung injury.
Integrated multi-omics and in vivo/in vitro work shows increased OGDH activity and decreased α‑KG in LPS-sepsis, with OGDH inhibition (CPI-613) suppressing M1-like alveolar macrophage polarization, reducing ferroptosis via Nrf2 activation, attenuating lung injury, and improving survival; patient sera showed elevated OGDH activity correlating with severity.
Impact: Identifies an actionable immunometabolic driver (OGDH) linking ferroptosis to sepsis lung injury with cross-species validation and a clinical assay for enzyme activity—bridging mechanism to potential early-phase therapeutics.
Clinical Implications: OGDH activity could become a biomarker to identify hyperinflammatory sepsis-ALI and support patient selection for early-phase trials of OGDH inhibitors (e.g., CPI-613), though human interventional data are needed.
Key Findings
- LPS-sepsis mice had decreased α‑ketoglutarate and increased OGDH activity.
- OGDH inhibition (CPI-613) reduced M1-like macrophage polarization, ferroptosis markers, lung injury, systemic inflammation, and improved survival via Nrf2 activation.
- Patient sera from sepsis-associated ARDS showed elevated OGDH activity correlating with severity and outcomes.